{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:31:49Z","timestamp":1788510709389,"version":"build-2803163510"},"reference-count":45,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,7,1]]},"abstract":"<jats:p> PURPOSE: To identify the role of p53 pathway alteration(s) as predictors of treatment outcome in patients with advanced, resectable, squamous cell carcinoma (SCC) of the larynx and pharynx treated with larynx preservation (LP) intent. <\/jats:p><jats:p> PATIENTS AND METHODS: Seventy-one patients treated on two consecutive LP protocols were studied based on availability of representative tissues. We analyzed the expression pattern of p53, its upstream regulator mdm2, and downstream transcriptional target p21\/WAF1 by immunohistochemistry. Positive phenotype was defined as \u2265 20% of tumor cells showing nuclear immunoreactivity. Results were correlated with treatment outcomes. <\/jats:p><jats:p> RESULTS: Positive phenotype was observed in 35 (49%) of 71 cases for p53, in 52 (74%) of 70 for mdm2, and in 37 (54%) of 68 for p21. There was no correlation between p53 phenotype and p21 nuclear accumulation. The mdm2-negative phenotype was most predictive of major response at the primary tumor site (P = .088). p53-positive phenotype was associated with worse local control with LP (LCLP; 49% v 23%, P = .053) and inferior overall survival (OS; 51% v 29%, P = .017) at 5 years. On Cox regression analysis, p53-positive phenotype predicted inferior OS (P = .033) and showed a trend for worse LCLP (P = .102). When analyzed in a multivariate model as continuous variables, p53 showed a stronger correlation with inferior OS (P &lt; .01), and mdm2 was associated with worse OS (P &lt; .01). <\/jats:p><jats:p> CONCLUSION: Among the three markers studied, our data support p53 phenotype as the most informative predictor of unfavorable outcomes in the LP setting, and suggest a role for mdm2 phenotype that requires further exploration. Our analysis does not support a p53-dependent mechanism for p21 expression. Prospective and larger studies are necessary before integration of these molecular markers as part of molecular staging and predictors for organ preservation or other outcomes. <\/jats:p>","DOI":"10.1200\/jco.2002.06.161","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T20:11:44Z","timestamp":1034367104000},"page":"2980-2987","source":"Crossref","is-referenced-by-count":46,"title":["Alteration of p53 Pathway in Squamous Cell Carcinoma of the Head and Neck: Impact on Treatment Outcome in Patients Treated With Larynx Preservation Intent"],"prefix":"10.1200","volume":"20","author":[{"given":"Iman","family":"Osman","sequence":"first","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sherman","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvanesh","family":"Singh","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennapadam","family":"Venkatraman","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zelefsky","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bosl","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Scher","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Shah","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Shaha","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Kraus","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cordon-Cardo","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Pfister","sequence":"additional","affiliation":[{"name":"From the Departments of Medicine, Radiation Oncology, Surgery, Pathology, and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-110662","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106133242402"},{"key":"R2-110662","doi-asserted-by":"crossref","unstructured":"Lefebvre  JL,   Chevalier  D,   Luboinski  B,  et al:   Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial:  EORTC Head and Neck Cancer Cooperative Group.   Cancer 88:  890,1996-899,","DOI":"10.1093\/jnci\/88.13.890"},{"key":"R3-110662","doi-asserted-by":"publisher","DOI":"10.1016\/S1055-3207(18)30302-8"},{"key":"R4-110662","unstructured":"Gottschlich  S,   Maune  S,   Preugschat  J,  et al:   p53 analysis of laryngeal cancer in exon 4 to 9.  Anticancer Res 20:  2613,2000-2616,"},{"key":"R5-110662","doi-asserted-by":"publisher","DOI":"10.1007\/s004050050168"},{"key":"R6-110662","unstructured":"Nakashima  S,   Natsugoe  S,   Matsumoto  M,  et al:   Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma.  Anticancer Res 20:  1933,2000-1937,"},{"key":"R7-110662","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1346"},{"key":"R8-110662","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(99)00393-6"},{"key":"R9-110662","doi-asserted-by":"publisher","DOI":"10.1016\/S0901-5027(00)80122-8"},{"key":"R10-110662","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81774-2"},{"key":"R11-110662","doi-asserted-by":"publisher","DOI":"10.1007\/s000180050273"},{"key":"R12-110662","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.51.36031"},{"key":"R13-110662","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1991.tb07676.x"},{"key":"R14-110662","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.26.15608"},{"key":"R15-110662","doi-asserted-by":"crossref","unstructured":"Bureik  M,   Jungbluth  A,   Drescher  R,  et al:   Human p53 restores DNA synthesis control in fission yeast.  Biol Chem 378:  1361,1997-1371,","DOI":"10.1515\/bchm.1997.378.11.1361"},{"key":"R16-110662","doi-asserted-by":"publisher","DOI":"10.1159\/000020284"},{"key":"R17-110662","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4644(20000615)77:4<569::AID-JCB5>3.0.CO;2-K"},{"key":"R18-110662","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.671"},{"key":"R19-110662","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1994.01880250077011"},{"key":"R21-110662","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90689-2"},{"key":"R22-110662","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R23-110662","doi-asserted-by":"publisher","DOI":"10.1378\/chest.87.3.368"},{"key":"R24-110662","doi-asserted-by":"crossref","unstructured":"Cordon-Cardo  C,   Dalbagni  G,   Saez  GT,  et al:   p53 mutations in human bladder cancer:  Genotypic versus phenotypic patterns.   Cancer 56:  347,1994-353,","DOI":"10.1002\/ijc.2910560309"},{"key":"R25-110662","doi-asserted-by":"publisher","DOI":"10.1097\/00019606-199300020-00002"},{"key":"R26-110662","unstructured":"Osman  I,   Drobnjak  M,   Fazzari  M,  et al:   Inactivation of the p53 pathway in prostate cancer:  Impact on tumor progression.   Clin Cancer Res 5:  2082,1999-2088,"},{"key":"R27-110662","unstructured":"Osman  I,   Scher  HI,   Zhang  ZF,  et al:   Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.  Clin Cancer Res 3:  531,1997-536,"},{"key":"R28-110662","unstructured":"Cordon-Cardo  C,   Latres  E,   Drobnjak  M,  et al:   Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.  Cancer Res 54:  794,1994-799,"},{"key":"R30-110662","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R31-110662","doi-asserted-by":"crossref","unstructured":"Cox  DR:   Regression models and life-tables.  J Royal Stat Soc 34:  187,1972-220,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R32-110662","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"R33-110662","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.385"},{"key":"R34-110662","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(200005)191:1<33::AID-PATH585>3.0.CO;2-B"},{"key":"R35-110662","doi-asserted-by":"publisher","DOI":"10.1016\/S0194-5998(95)70077-3"},{"key":"R36-110662","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1997.01900060047008"},{"key":"R37-110662","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1997.9.2.113"},{"key":"R38-110662","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215100140769"},{"key":"R39-110662","unstructured":"Sato  N,   Mizumoto  K,   Maehara  N,  et al:   Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1\/CIP1.  Anticancer Res 20:  837,2000-842,"},{"key":"R40-110662","doi-asserted-by":"crossref","unstructured":"Wang  H,   Zeng  X,   Oliver  P,  et al:   MDM2 oncogene as a target for cancer therapy:  An antisense approach.   Int J Oncol 15:  653,1999-660,","DOI":"10.3892\/ijo.15.4.653"},{"key":"R41-110662","doi-asserted-by":"crossref","unstructured":"Maiorano  E,   Botticella  MA,   Marzullo  A,  et al:   Expression of ER-D5 and EGFr in laryngeal carcinoma and pre-malignant epithelium.  Acta Otolaryngol Suppl 527:  95,1997-99,","DOI":"10.3109\/00016489709124045"},{"key":"R42-110662","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(97)00169-4"},{"key":"R43-110662","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R"},{"key":"R44-110662","doi-asserted-by":"crossref","unstructured":"Van Oijen  MG,   Tilanus  MG,   Medema  RH,  et al:   Expression of p21 (Waf1\/Cip1) in head and neck cancer in relation to proliferation, differentiation, p53 status and cyclin D1 expression.  J Oral Pathol Med 27:  367,1998-375,","DOI":"10.1111\/j.1600-0714.1998.tb01969.x"},{"key":"R45-110662","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.54.11.866"},{"key":"R46-110662","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19990901)40:4<256::AID-PROS7>3.0.CO;2-I"},{"key":"R47-110662","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.15.1054"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.06.161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:51:21Z","timestamp":1653515481000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.06.161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,1]]},"references-count":45,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2002,7,1]]}},"alternative-id":["10.1200\/JCO.2002.06.161"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.06.161","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7,1]]}}}